(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) jumped 9.05% to $7.11 at 11:59 EST on Monday, after five sequential sessions in a row of losses. NASDAQ is jumping 0.93% to $11,242.75, after two successive sessions in a row of losses. This seems, as yet, a somewhat positive trend trading session today.
Novavax’s last close was $6.52, 92.38% below its 52-week high of $85.60.
About Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
Moving Average
Novavax’s worth is way under its 50-day moving average of $10.13 and way under its 200-day moving average of $27.94.
More news about Novavax (NVAX).
